Metagenomi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	30.91	52.3	44.76	17.2	0.24
Revenue Growth (YoY)	-43.88%	16.84%	160.21%	6978.19%	-
Gross Profit	30.91	52.3	44.76	17.2	0.24
Selling, General & Admin	27.09	32.02	28.85	18.7	9.71
Research & Development	96.1	109.18	94.4	43.14	14.48
Total Operating Expenses	123.18	141.2	123.25	61.84	24.19
Operating Income	-92.27	-88.9	-78.49	-44.64	-23.95
Total Non-Operating Income (Expense)	2.23	5.33	18.26	3.62	-
Pretax Income	-90.04	-83.57	-60.23	-41.02	-21.44
Provision for Income Taxes	-1.3	-5.51	8.03	2.57	-
Net Income	-88.74	-78.06	-68.26	-43.59	-21.44
Net Income to Common	-88.74	-78.06	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	37	33	3	3	6
Shares Outstanding (Diluted)	37	33	3	3	6
Shares Change (YoY)	51.97%	870.10%	0.15%	-42.84%	-
EPS (Basic)	-2.40	-2.36	-20.05	-12.82	-3.61
EPS (Diluted)	-2.40	-2.36	-20.05	-12.82	-3.61
Free Cash Flow	-92.45	-112.19	-101.22	15.75	21.35
Free Cash Flow Growth	-	-	-	-26.26%	-
Free Cash Flow Per Share	-2.48	-3.40	-29.73	4.63	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-298.48%	-170.00%	-175.38%	-259.53%	-9854.73%
Profit Margin	-287.06%	-149.26%	-152.50%	-253.45%	-8823.87%
FCF Margin	-299.05%	-214.53%	-226.17%	91.55%	8787.65%
EBITDA	-86.79	-83.49	-74.29	-42.91	-23.56
EBITDA Margin	-280.76%	-159.66%	-165.98%	-249.46%	-9695.47%
EBIT	-92.27	-88.9	-78.49	-44.64	-23.95
EBIT Margin	-298.48%	-170.00%	-175.38%	-259.53%	-9854.73%
Effective Tax Rate	1.44%	6.60%	-13.33%	-6.26%	0.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q